AI Article Synopsis
- The study evaluated the properties of a calcium-doped zinc oxide paste compared to calcium hydroxide, focusing on cytotoxicity, radiopacity, pH, and penetration in dentinal tubules.
- ZnO:1.0Ca pastes demonstrated lower cell viability and pH levels than Ca(OH), but offered superior radiopacity and deeper dentinal tubule penetration.
- Overall, while ZnO:1.0Ca showed advantages in radiopacity and penetrability, Ca(OH) maintained higher cell viability and pH levels.
Article Abstract
Objectives: This study investigated the cytotoxicity, radiopacity, pH, and dentinal tubule penetration of a paste of 1.0% calcium-doped zinc oxide nanocrystals (ZnO:1.0Ca) combined with propylene glycol (PRG) or polyethylene glycol and propylene glycol (PEG-PRG).
Materials And Methods: The pastes were prepared by mixing calcium hydroxide [Ca(OH)] or ZnO:1.0Ca with PRG or a PEG-PRG mixture. The pH was evaluated after 24 and 96 hours of storage in deionized water. Digital radiographs were acquired for radiopacity analysis and bubble counting of each material. The materials were labeled with 0.1% fluorescein and applied to root canals, and images of their dentinal tubule penetration were obtained using confocal laser scanning microscopy. RAW264.7 macrophages were placed in different dilutions of culture media previously exposed to the materials for 24 and 96 hours and tested for cell viability using the MTT assay. Analysis of variance and the Tukey test ( = 0.05) were performed.
Results: ZnO:1.0Ca materials showed lower viability at 1:1 and 1:2 dilutions than Ca(OH) materials ( < 0.0001). Ca(OH) had higher pH values than ZnO:1.0Ca at 24 and 96 hours, regardless of the vehicle ( < 0.05). ZnO:1.0Ca pastes showed higher radiopacity than Ca(OH) pastes ( < 0.01). No between-material differences were found in bubble counting ( = 0.0902). The ZnO:1.0Ca pastes had a greater penetration depth than Ca(OH) in the apical third ( < 0.0001).
Conclusions: ZnO:1.0Ca medicaments presented higher penetrability, cell viability, and radiopacity than Ca(OH). Higher values of cell viability and pH were present in Ca(OH) than in ZnO:1.0Ca.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715372 | PMC |
| http://dx.doi.org/10.5395/rde.2022.47.e38 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurotrophomodulatory effect of TNF-α through NF-κB in rat cortical astrocytes.
Cytotechnology
February 2025
Division of Neurobiology, Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat India.
Tumor necrosis factor alpha (TNF-α) is a well-known pro-inflammatory cytokine originally recognized for its ability to induce apoptosis and cell death. However, recent research has revealed that TNF-α also plays a crucial role as a mediator of cell survival, influencing a wide range of cellular functions. The signaling of TNF-α is mediated through two distinct receptors, TNFR1 and TNFR2, which trigger various intracellular pathways, including NF-κB, JNK, and caspase signaling cascades.
View Article and Find Full Text PDFEfficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.
Mol Clin Oncol
February 2025
Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, P.R. China.
The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.
View Article and Find Full Text PDFEBV-specific T-cell immunity: relevance for multiple sclerosis.
Front Immunol
December 2024
Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Genetic and environmental factors jointly determine the susceptibility to develop multiple sclerosis (MS). Improvements in the design of epidemiological studies have helped to identify consistent environmental risk associations such as the increased susceptibility for MS following Epstein-Barr virus (EBV) infection, while biological mechanisms that drive the association between EBV and MS remain incompletely understood. An increased and broadened repertoire of antibody and T-cell immune responses to EBV-encoded antigens, especially to the dominant CD4 T-cell EBV nuclear antigen 1 (EBNA1), is consistently observed in patients with MS, indicating that protective EBV-specific immune responses are deregulated in MS and potentially contribute to disease development.
View Article and Find Full Text PDFOptimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma.
Front Immunol
December 2024
Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Introduction: Challenges remain in reducing antigen escape and tumor recurrence while CAR-T cell therapy has substantially improved outcomes in the treatment of multiple myeloma. T cell receptor fusion construct (TRuC)-T cells, which utilize intact T cell receptor (TCR)-CD3 complex to eliminate tumor cells in a non-major histocompatibility complex (MHC)-restricted manner, represent a promising strategy. Moreover, interleukin-7 (IL-7) is known to enhance the proliferation and survival of T cells.
View Article and Find Full Text PDFThe systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model.
Front Immunol
December 2024
Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Afliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Background: Inflammation and immune evasion are associated with tumorigenesis and progression. The Systemic Inflammation Response Index (SIRI) has been proposed as a pre-treatment peripheral blood biomarker. This study aims to compare the relationship between SIRI, various serum biomarkers, and the prognosis of NSCLC patients before and after treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!